Human RCTPubMed ID: 37840095·2023

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Wadden TA, Chao AM, Machineni S, et al.

Nature Medicine, 2023 · n = 579

Key finding

Tirzepatide enhanced and sustained weight loss beyond lifestyle intervention alone, producing total weight reduction exceeding 24%.

Summary

Trial showing tirzepatide produced additional 18.4% weight loss on top of 6% from intensive lifestyle intervention, vs 2.5% weight regain with placebo.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot

Tirzepatide Preserves Kidney Function in Type 2 Diabetes

American Journal of Kidney Diseases · 2023 · Human RCT